These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

43 related articles for article (PubMed ID: 21138645)

  • 21. Viral interaction and responses in chronic hepatitis C and B coinfected patients with interferon-alpha plus ribavirin combination therapy.
    Chuang WL; Dai CY; Chang WY; Lee LP; Lin ZY; Chen SC; Hsieh MY; Wang LY; Yu ML
    Antivir Ther; 2005; 10(1):125-33. PubMed ID: 15751770
    [TBL] [Abstract][Full Text] [Related]  

  • 22. An uncommon presentation of the co-existence of morphea and vitiligo in a patient with chronic hepatitis B virus infection: is there a possible association with autoimmunity?
    Soylu S; Gül U; Gönül M; Kiliç A; Cakmak SK; Demiriz M
    Am J Clin Dermatol; 2009; 10(5):336-8. PubMed ID: 19658447
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Anti-viral treatment: pro or cons type I IFN?].
    Whitehead P; Drouet B; Zagury D; Bensussan A
    Med Sci (Paris); 2013 Oct; 29(10):836-9. PubMed ID: 24148119
    [No Abstract]   [Full Text] [Related]  

  • 24. Interferon-induced vitiligo in a patient with chronic viral hepatitis C infection.
    Simsek H; Savas C; Akkiz H; Telatar H
    Dermatology; 1996; 193(1):65-6. PubMed ID: 8864627
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant interferon-alpha therapy and meno-metrorrhagia.
    Uberti-Foppa C; Finazzi R; De Bona A
    Br J Obstet Gynaecol; 1998 Mar; 105(3):367-8. PubMed ID: 9533004
    [No Abstract]   [Full Text] [Related]  

  • 26. Interferon alpha-induced lupus: proof of principle.
    Niewold TB
    J Clin Rheumatol; 2008 Jun; 14(3):131-2. PubMed ID: 18525429
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pathological consequences of excess of interferon in vivo].
    Lebon P; Crow YJ; Casanova JL; Gresser I
    Med Sci (Paris); 2019 Mar; 35(3):232-235. PubMed ID: 30931907
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiple sclerosis and human interferon alfa.
    Coyle JT
    JAMA; 1989 Nov; 262(19):2684. PubMed ID: 2624644
    [No Abstract]   [Full Text] [Related]  

  • 29. Role of Amine Neurotransmitters and Their Receptors in Skin Pigmentation: Therapeutic Implication.
    Enkhtaivan E; Lee CH
    Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360837
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interferon-alfa in the treatment of chronic hepatitis B.
    Zhang FK
    Hepatobiliary Pancreat Dis Int; 2004 Aug; 3(3):337-40. PubMed ID: 15313664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Concomitant vitiligo and psoriasis in a patient treated with interferon alfa-2a for chronic hepatitis B infection.
    Seçkin D; Durusoy C; Sahin S
    Pediatr Dermatol; 2004; 21(5):577-9. PubMed ID: 15461767
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interferon-induced vitiligo in hepatitis C patients: a case series.
    Hamadah I; Binamer Y; Sanai FM; Abdo AA; Alajlan A
    Int J Dermatol; 2010 Jul; 49(7):829-33. PubMed ID: 20618507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Recombinant interferon-alfa therapy in children with chronic hepatitis B and cured cancer.
    Koçak N; Ozen H; Saltik IN; Yüce A; Gürakan F
    Indian J Gastroenterol; 2000; 19(4):197-8. PubMed ID: 11059197
    [No Abstract]   [Full Text] [Related]  

  • 34. [Vitiligo and alopecia in patients with chronic hepatitis C treated with alpha interferon associated or not with ribavirin].
    Primo J; Merino C; Gómez Belda AB
    Gastroenterol Hepatol; 2000; 23(7):362-3. PubMed ID: 11002542
    [No Abstract]   [Full Text] [Related]  

  • 35. [A case report of concomitant vitiligo in a patient treated with interferon alfa-1b for chronic hepatitis B infection].
    Hu MF; Li YL; Zhuang L
    Zhonghua Gan Zang Bing Za Zhi; 2010 Nov; 18(11):872. PubMed ID: 21138645
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.